These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22095569)

  • 1. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.
    Keenan JD; Ayele B; Gebre T; Moncada J; Stoller NE; Zhou Z; Porco TC; McCulloch CE; Gaynor BD; Emerson PM; Schachter J; Lietman TM
    Clin Infect Dis; 2012 Jan; 54(2):253-6. PubMed ID: 22095569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for ocular chlamydia after three mass azithromycin distributions.
    Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.
    Keenan JD; See CW; Moncada J; Ayele B; Gebre T; Stoller NE; McCulloch CE; Porco TC; Gaynor BD; Emerson PM; Schachter J; Lietman TM
    Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):235-40. PubMed ID: 22159017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
    Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
    Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
    Biebesheimer JB; House J; Hong KC; Lakew T; Alemayehu W; Zhou Z; Moncada J; Rogér A; Keenan J; Gaynor BD; Schachter J; Lietman TM
    Ophthalmology; 2009 Nov; 116(11):2047-50. PubMed ID: 19744717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of Mass Azithromycin Distribution for Ocular Chlamydia in a Trachoma Endemic Region of Ethiopia: A Cluster Randomized Trial.
    Lietman TM; Ayele B; Gebre T; Zerihun M; Tadesse Z; Emerson PM; Nash SD; Porco TC; Keenan JD; Oldenburg CE
    Am J Ophthalmol; 2020 Jun; 214():143-150. PubMed ID: 32171768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
    Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
    Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.
    West SK; Munoz B; Mkocha H; Gaydos CA; Quinn TC
    J Infect Dis; 2011 Jul; 204(2):268-73. PubMed ID: 21673038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.
    Edwards T; Harding-Esch EM; Hailu G; Andreason A; Mabey DC; Todd J; Cumberland P
    Trop Med Int Health; 2008 Apr; 13(4):556-65. PubMed ID: 18282237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
    Porco TC; Gebre T; Ayele B; House J; Keenan J; Zhou Z; Hong KC; Stoller N; Ray KJ; Emerson P; Gaynor BD; Lietman TM
    JAMA; 2009 Sep; 302(9):962-8. PubMed ID: 19724043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Chlamydia trachomatis ocular infection in trachoma-endemic communities by rRNA amplification.
    Yang JL; Hong KC; Schachter J; Moncada J; Lekew T; House JI; Zhou Z; Neuwelt MD; Rutar T; Halfpenny C; Shah N; Whitcher JP; Lietman TM
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):90-4. PubMed ID: 18689701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma.
    Yang JL; Schachter J; Moncada J; Habte D; Zerihun M; House JI; Zhou Z; Hong KC; Maxey K; Gaynor BD; Lietman TM
    Br J Ophthalmol; 2007 Mar; 91(3):293-5. PubMed ID: 17050583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rationale for continuing mass antibiotic distributions for trachoma.
    Ray KJ; Porco TC; Hong KC; Lee DC; Alemayehu W; Melese M; Lakew T; Yi E; House J; Chidambaram JD; Whitcher JP; Gaynor BD; Lietman TM
    BMC Infect Dis; 2007 Aug; 7():91. PubMed ID: 17683646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
    Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.